Oral Terbinafine: Indications, Dosing, and Contraindications
Oral terbinafine 250 mg daily is the first-line systemic treatment for fungal nail infections (onychomycosis) in adults without liver disease, dosed for 12-16 weeks for toenails and 6-8 weeks for fingernails. 12
Primary Indication
Onychomycosis (fungal nail infection) caused by dermatophytes is the main FDA-approved indication 2. Confirm diagnosis with laboratory testing (KOH preparation, fungal culture, or nail biopsy) before initiating treatment 2.
Adult Dosing Regimens
Standard Dosing
- Toenail onychomycosis: 250 mg once daily for 12-16 weeks 12
- Fingernail onychomycosis: 250 mg once daily for 6-8 weeks 12
The optimal clinical effect appears months after treatment cessation due to the time required for healthy nail outgrowth 2. This reflects terbinafine's fungicidal mechanism and residual tissue effect 3.
Off-Label Uses
While not FDA-approved, terbinafine has demonstrated efficacy in:
- Tinea capitis (scalp ringworm)
- Tinea pedis (athlete's foot)
- Tinea corporis/cruris (body/groin ringworm)
These typically require shorter treatment courses (2-4 weeks) 34.
Pediatric Dosing (Off-Label)
Weight-based dosing for children 5:
- <20 kg: 62.5 mg daily
- 20-40 kg: 125 mg daily
- >40 kg: 250 mg daily (adult dose)
Duration: 4 weeks for tinea capitis; longer for onychomycosis 645
The 2026 British Association of Dermatologists guideline recommends initiating shared decision-making with parents/carers when prescribing off-label systemic therapy for children, ensuring adherence to local pediatric prescribing policies and seeking specialist advice 1.
Absolute Contraindications
History of allergic reaction to oral terbinafine due to anaphylaxis risk 22
Major Contraindications and Warnings
Hepatotoxicity (Critical Warning)
Do not prescribe terbinafine to patients with chronic or active liver disease 2. Liver failure leading to transplant or death has occurred in patients with and without pre-existing liver disease 22.
- Obtain baseline liver function tests before treatment
- Consider periodic monitoring during treatment
- Immediately discontinue if liver injury develops
Instruct patients to stop terbinafine and seek immediate medical attention for 2:
- Right upper quadrant abdominal pain
- Persistent nausea, anorexia, fatigue, or vomiting
- Dark urine or pale stools
- Jaundice
Taste and Smell Disturbances
Discontinue terbinafine if taste or smell disturbances occur 22. These can be:
- Severe enough to cause decreased food intake and weight loss
- Prolonged (>1 year) or permanent
- Associated with depressive symptoms 2
Severe Skin Reactions
Immediately discontinue if signs of 2:
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Erythema multiforme
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
Hematologic Effects
Discontinue if neutrophil count ≤1,000 cells/mm³ 22. Consider monitoring complete blood counts in immunodeficient patients if treatment exceeds 6 weeks 2.
Depressive Symptoms
Monitor for and instruct patients to report depressive symptoms during treatment 22.
Important Drug Interactions
Terbinafine is a CYP2D6 inhibitor 27. Key interactions include:
- Tamoxifen: Avoid combination - terbinafine reduces conversion to active metabolite endoxifen, diminishing tamoxifen efficacy 7
- Tricyclic antidepressants and SSRIs/SNRIs: Monitor clinical response and side effects 7
- Other CYP2D6 substrates: desipramine, certain antipsychotics, cardiovascular drugs 27
Terbinafine has relatively low interaction potential compared to azole antifungals, making it suitable for elderly and multimorbid patients 7.
Clinical Positioning
Terbinafine is superior to itraconazole and fluconazole for dermatophyte toenail onychomycosis 83, achieving mycological cure rates of approximately 76% in meta-analyses 8. The 2026 British guidelines give it the highest recommendation level (↑↑) as first-line therapy 111.
Switch to itraconazole (200 mg daily for 12-16 weeks for toenails, 6-8 weeks for fingernails) if terbinafine is contraindicated or not tolerated 1.
Emerging Resistance Concern
For Trichophyton indotineae (T. mentagrophytes genotype VIII), which is often terbinafine-resistant, consider itraconazole as first-line therapy instead 9. Suspect this organism in patients with extensive or terbinafine-recalcitrant dermatophytosis, particularly with travel history to endemic regions 9.